Science Explorer Back to mapMap
Discussion
Topic · Dermatology

Chemotherapy-related skin toxicity

Chemotherapy-related skin toxicity is a research topic within Dermatology. Science Explorer counts 13k research works in it since 1950. 10.4% of them reached the world's top 10% most cited for their field and year.

This cluster of papers focuses on the dermatological side effects and complications associated with chemotherapy, including extravasation of antineoplastic agents, hand-foot syndrome, radiation recall dermatitis, and nail changes. It also discusses the management and prevention strategies for these chemotherapy-induced dermatological toxicities.

  • Chemotherapy
  • Dermatological Toxicity
  • Extravasation
  • Hand-Foot Syndrome
  • Radiation Recall
  • Pegylated Liposomal Doxorubicin
  • Management
  • Erythrodysesthesia
  • Nail Changes
  • Prevention
Research works
13k
fractional, since 1950
In the world top 10%
1.3k
per year above
Top-10% rate
10.4%
share of its works in the world top 10%
Growth, 2018-21 → 2022-25
+17%
the tick is no change
Largest producer
United States
37% of the 10 largest, 2022-now
Chemotherapy-related skin toxicity

This ranks research output and citation impact. It says nothing about the quality of diagnosis, treatment or care.

Which countries lead Chemotherapy-related skin toxicity research?

By volume, the United States and China publish the most (678 and 239 works in 2022-now).

By volume, 2022-now

  1. 1 United States 678 works
  2. 2 China 239 works
  3. 3 India 207 works
  4. 4 Japan 173 works
  5. 5 Brazil 111 works
  6. 6 France 98 works
  7. 7 Spain 96 works
  8. 8 Italy 92 works
  9. 9 Germany 82 works
  10. 10 United Kingdom 69 works

How concentrated that is

The same countries as shares of everything the list above accounts for. A node where two countries do two thirds of the work and one spread evenly across twelve read alike as a ranking and not at all alike here.

United States: 36.8%China: 13.0%India: 11.2%Japan: 9.4%6 others listed: 29.7%37%largest
United States678 · 36.8%China239 · 13.0%India207 · 11.2%Japan173 · 9.4%6 others listed548 · 29.7%

Shares of the rows listed above, not of the whole node.

Which institutions lead Chemotherapy-related skin toxicity research?

By volume in 2022-now, Harvard University publishes the most Chemotherapy-related skin toxicity research, followed by All India Institute of Medical Sciences and Mayo Clinic.

By volume, 2022-now

  1. 1 Harvard UniversityUnited States 25 works
  2. 2 All India Institute of Medical SciencesIndia 25 works
  3. 3 Mayo ClinicUnited States 19 works
  4. 4 University of TorontoCanada 12 works
  5. 5 Memorial Sloan Kettering Cancer CenterUnited States 11 works
  6. 6 University of MiamiUnited States 10 works
  7. 7 Yale UniversityUnited States 10 works
  8. 8 Cornell UniversityUnited States 10 works
  9. 9 Sun Yat-sen UniversityChina 10 works
  10. 10 InsermFrance 10 works

Who are the leading researchers in Chemotherapy-related skin toxicity?

The most-cited researchers publishing on Chemotherapy-related skin toxicity include Gregory Y.H. Lip, Hagop M. Kantarjian and Ralph B. D’Agostino.

  1. 1 Gregory Y.H. Lip United Kingdom 311k citations
  2. 2 Hagop M. Kantarjian United States 273k citations
  3. 3 Ralph B. D’Agostino United States 255k citations
  4. 4 Marco A. Marra Canada 245k citations

Ranked by citations received across their whole record, among researchers with at least three works on this topic.

What are the most cited papers in Chemotherapy-related skin toxicity?

The most cited paper in Chemotherapy-related skin toxicity is "Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy" (Norikazu Masuda et al., 2017), with 1,947 citations. Next come "Paclitaxel (Taxol)" (1,879) and "The side effects of platinum-based chemotherapy drugs: a review for chemists" (1,735).

Most cited papers
#PaperReleasedCitations
1 Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy Norikazu Masuda et al. · New England Journal of Medicine Open access 31 May 2017 1,947
2 Paclitaxel (Taxol) Eric Keith Rowinsky, Ross C. Donehower · New England Journal of Medicine 13 Apr 1995 1,879
3 The side effects of platinum-based chemotherapy drugs: a review for chemists Rabbab Oun, Yvonne E. Moussa, Nial Wheate · Dalton Transactions 2018 1,735
4 Cremophor EL Hans A. J. Gelderblom, Jaap Verweij, Kees Nooter et al. · European Journal of Cancer Sep 2001 1,658
5 Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis Marta Seretny, Gillian L. Currie, Emily S. Sena et al. · Pain ReviewOpen access 23 Sep 2014 1,585
All 100 most cited papers, with filters and sorting

Where is Chemotherapy-related skin toxicity research done?

The largest centres of Chemotherapy-related skin toxicity research in 2022-now are Tokyo (Japan), New York (United States), Beijing (China) and New Delhi (India).

Largest cities, 2022-now

  1. 1 TokyoJapan 41 works
  2. 2 New YorkUnited States 40 works
  3. 3 BeijingChina 28 works
  4. 4 New DelhiIndia 27 works
  5. 5 São PauloBrazil 24 works
  6. 6 ParisFrance 24 works
  7. 7 BostonUnited States 23 works
  8. 8 GuangzhouChina 21 works
  9. 9 LondonUnited Kingdom 19 works
  10. 10 SeoulSouth Korea 19 works
See Chemotherapy-related skin toxicity on the map

Where is the best place to study Chemotherapy-related skin toxicity?

Among universities, judged by research, Harvard University, University of Miami and University of Naples Federico II score highest, combining citation excellence, specialisation, size, growth and international reach. Research strength is one signal when choosing where to study; it does not measure teaching.

0%20%40%mean 17.25%fractional works in this field (log) →share of work in the world top 10% →University of MiamiUniversity of Naples…University of TorontoHarvard University
above the meannear itbelow it

One dot per university in the first ten of the table below, at the default weights. The upper left is the interesting corner: small places doing unusually strong work.

Citation excellenceshare of its work in the world top 10%, 2022-now and all time averaged
40%
Specialisationhow much of its work is in this field, counted up to 10× the world share
10%
Sizeits output in this field, on a log scale
30%
Growthoutput growth, counted from -20% to +20%
10%
Internationalshare of its work with a co-author abroad
10%
Each slider sets a weight; the share it gets of the score is beside it.
#UniversityScoreTop 10%SpecialisationWorksGrowth
1Harvard UniversityUnited States 80.216.1%3.5×25 +21.5%
2University of MiamiUnited States 63.529.0%7.2×10 +17.7%
3University of Naples Federico IIItaly 61.825.1%5.0×8 +91.7%
4University of TorontoCanada 54.117.9%2.6×12 -6.6%
5All India Institute of Medical SciencesIndia 52.03.2%9.9×24 +86.1%
6Yale UniversityUnited States 50.522.1%4.0×10 +4.7%
7University of MichiganUnited States 45.823.9%2.5×9 -5.3%
8Albert Einstein College of MedicineUnited States 44.313.8%11.6×9 +19.1%
9New York UniversityUnited States 40.616.6%3.2×8 +63.4%
10Cornell UniversityUnited States 40.34.8%3.3×10 +82.0%

Universities only. The score blends citation excellence (40%), size (30%), specialisation (10%), growth (10%), international reach (10%), 2022-now; growth compares 2018-21 with 2022-25 and counts up to +20%, since a jump from a small base is mostly noise.

Every institution in Chemotherapy-related skin toxicity, country by country

Is Chemotherapy-related skin toxicity research growing?

Output in 2022-2025 was 17% higher than in 2018-2021, peaking in 2025. The fastest-growing topics are Chemotherapy-related skin toxicity.

still counting19801990200020102020
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Its share of all research

Growing output can still be a shrinking share: all of science grows. This is Chemotherapy-related skin toxicity as a percentage of every work published that year, 0.011% in 2024.

still counting0.010%0.020%Chemotherapy-related skin toxicity0.011% in 202519801990200020102020

Fractional works of Chemotherapy-related skin toxicity over all fractional works that year. How the balance of science has shifted.

How much of it reaches the world top 10%

Year by year.

still counting5%10%15%Chemotherapy-related skin toxicity10.1% in 2025200020102020

Of each year's works in it, the share that reached the world's 10% most cited for their field and year. A field is the world for its own topics, so there is no other line to hold it against.

Which topics inside it are moving

Growth and decline on one axis around a shared zero. Two lists side by side hide the thing that matters: whether the growth dwarfs the decline, or the other way round.

Discussion

Ask a question or share a note about Chemotherapy-related skin toxicity. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.